Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) motto is: Never leave an investor uninformed

February 17, 2016 11:50am

Learn who is stumbling and what does the mumbling mean, like it or not, RMi is the only source of actionable intelligence for the stem, cell and gene therapy and regenerative medicine’s universe

To understand pricing, news and its circumstance, opinion and sentiment.

Subscribe … http://www.regmedinvestors.com/create-account

Fore warned is fore armed, leave no post unread, you’ll never know what you missed or I said about which company!

If you want to continue reading and smartly investing in the stem, cell and gene therapy, regenerative medicine sector, the easiest, fastest, and most effective way for you to get started is to subscribe … http://www.regmedinvestors.com/create-account

RMi provides you with actionable analysis, analytics and synthesis plus exclusive listing of “our” universe’s stocks with the potential for gains and losses.

2016 began with the worst January in recent memory; many sector “participants” appear to be repriced indiscriminately. What is the outlook for the rest of 2016?

The definition of expectation is provided here through context, interpretation and pricing metrics

Thanks again for following along with me these past six years!

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

4 hours 16 min ago
RegMed Investors (RMi) Closing Bell: welcoming the upside trend

13 hours 16 min ago
RegMed Investors’ (RMi) pre-open: finding our way

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.